Amneal Pharmaceuticals (AMRX) Consolidated Net Income (2017 - 2026)

Amneal Pharmaceuticals' Consolidated Net Income history runs 10 years deep, the most recent figure standing at $78.0 million for Q1 2026.

• On a quarterly basis, Consolidated Net Income rose 216.84% year-over-year to $78.0 million in Q1 2026; TTM through Mar 2026 was $181.3 million, a 459.27% increase from a year earlier, with the FY2025 full-year figure at $127.9 million, up 273.17% from the prior year.
• Consolidated Net Income rose to $78.0 million in Q1 2026 per AMRX's latest filing, from $49.6 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $78.0 million in Q1 2026 and bottomed at -$240.1 million in Q2 2022.
• The 5-year median for Consolidated Net Income is $11.8 million (2024), against an average of -$10.1 million.
• Biggest YoY gain for Consolidated Net Income was 1147.41% in 2023; the steepest drop was 1504.68% in 2023.
• Year by year, Consolidated Net Income stood at -$5.8 million in 2022, then tumbled by 1504.68% to -$93.3 million in 2023, then jumped by 77.78% to -$20.7 million in 2024, then soared by 339.0% to $49.6 million in 2025, then soared by 57.34% to $78.0 million in 2026.
• Per Business Quant, the three latest AMRX Consolidated Net Income figures stand at $78.0 million (Q1 2026), $49.6 million (Q4 2025), and $18.1 million (Q3 2025).